New method could help predict Alzheimer’s risk before symptoms start – study
While some treatments can ease symptoms, developing treatments that prevent or slow disease progression has been more challenging.
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Researchers have developed a new method that could help identify people who are at greater risk of developing Alzheimer’s disease before symptoms appear.
Experts suggest this could help speed up the creation of new treatments for the disease.
People with Alzheimer’s experience gradual loss of memory and other cognitive functions.
We developed a genetic predictor of Alzheimer’s disease associated with both clinical diagnosis and age-dependent cognitive decline
And while some treatments can ease symptoms, developing treatments that prevent or slow disease progression has been more challenging.
Senior author Dr Amit Khera said: “We developed a genetic predictor of Alzheimer’s disease associated with both clinical diagnosis and age-dependent cognitive decline.
“By studying the circulating proteome of healthy individuals with very high versus low inherited risk, our team nominated new biomarkers of neurocognitive disease.”
Some trials looking at potential treatments may have been unsuccessful because they involved patients whose disease was too advanced to be treated, experts suggest.
Better methods to identify people at high risk of developing the condition could aid treatment research.
In the new study Manish Paranjpe of the Broad Institute of MIT and Harvard in the US and colleagues analysed data on 7.1 million common DNA variants – alterations to the standard DNA sequence – from an earlier study that included tens of thousands of people with or without Alzheimer’s.
Using this data they developed a novel method that predicts a person’s risk of Alzheimer’s, depending on which DNA variants the person has.
The method was refined and validated with data from more than 300,000 additional people.
Researchers say their DNA-based method is unlikely to be suitable for doctors to predict a patient’s risk of Alzheimer’s because it may be less accurate for non-European populations.
The findings are published in Plos Genetics.